Showing posts with label neeoadjuvant chemo. Show all posts
Showing posts with label neeoadjuvant chemo. Show all posts

Monday, 22 March 2010

Decrease in Breast Density in the Contralateral Normal Breast of Patients Receiving Neoadjuvant Chemotherapy: MR Imaging Evaluation

Decrease in Breast Density in the Contralateral Normal Breast of Patients Receiving Neoadjuvant Chemotherapy: MR Imaging Evaluation
Jeon-Hor Chen, Ke Nie, Shadfar Bahri, Chieh-Chih Hsu, Fei-Ting Hsu, Han-Ni Shih, Muqing Lin, Orhan Nalcioglu, and Min-Ying Su
Radiology 2010;255 44-52

Link to Journal

By using three-dimensional MR imaging, we have demonstrated that patients receiving chemotherapy showed reduction of breast density and that the effects were significant after initial treatment with one to two cycles of the doxorubicin and cyclophosphamide regimen

Thursday, 21 January 2010

Identification of Residual Breast Carcinoma Following Neoadjuvant Chemotherapy: Diffusion-weighted Imaging—Comparison with Contrast-enhanced MR Imagin

Identification of Residual Breast Carcinoma Following Neoadjuvant Chemotherapy: Diffusion-weighted Imaging—Comparison with Contrast-enhanced MR Imaging and Pathologic Findings
Reiko Woodhams, Satoko Kakita, Hirofumi Hata, Keiichi Iwabuchi, Masaru Kuranami, Shiva Gautam, Hiroto Hatabu, Shinichi Kan, Carolyn Mountford
Radiology February 2010 254:357-366

Link to Journal


Diffusion-weighted MR imaging without contrast medium may provide diagnostic ability equivalent to that of contrast-enhanced MR imaging in detection of residual breast cancer after neoadjuvant chemotherapy

Thursday, 28 May 2009

Predicting Pathologic Response to Neoadjuvant Chemotherapy in Breast Cancer by Using MR Imaging and Quantitative 1H MR Spectroscopy

Predicting Pathologic Response to Neoadjuvant Chemotherapy in Breast Cancer by Using MR Imaging and Quantitative 1H MR Spectroscopy
Hyeon-Man Baek, Jeon-Hor Chen, Ke Nie, Hon J. Yu, Shadfar Bahri, Rita S. Mehta, Orhan Nalcioglu, and Min-Ying Su
Radiology 2009;251 653-662

Link to Journal

The study results suggest that when the reduction in choline-containing compounds was higher than the reduction in tumor size, the tumor was more likely to achieve pathologic complete response